NRTI Backbone in HIV Treatment

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  2012-12-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11640830-000000000-00000PMID 23083109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

  2012cited by this paper
• Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

  2012cited by this paper
• A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

  2012cited by this paper
• A Role of Template Cleavage in Reduced Excision of Chain-Terminating Nucleotides by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing the M184V Mutation

  2012cited by this paper
• Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.

  2012cited by this paper
• Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

  2012cited by this paper
• Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria.

  2012cited by this paper
• A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi.

  2012cited by this paper
• Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

  2012cited by this paper
• Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir

  2012cited by this paper
• Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility

  2012cited by this paper
• Changes in Body Composition and Mitochondrial Dna in HIV-1-Infected Patients Switching to Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine: A Substudy of the Bicombo Trial

  2012cited by this paper
• High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

  2012cited by this paper
• Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

  2012cited by this paper
• The NRTI BMS‐986001 does not degrade mitochondrial DNA in long‐term primary cultures of cells isolated from human kidney, muscle and subcutaneous fat

  2012cited by this paper
• Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

  2012cited by this paper
• Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.

  2012cited by this paper
• Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique.

  2012cited by this paper
• Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

  2012cited by this paper
• Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

  2011cited by this paper
• Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid)

  2011cited by this paper
• Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

  2011cited by this paper
• Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis

  2011cited by this paper
• Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

  2011cited by this paper
• Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

  2011cited by this paper
• Tenofovir Renal Proximal Tubular Toxicity Is Regulated By OAT1 and MRP4 Transporters

  2011cited by this paper
• Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz

  2011cited by this paper
• Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

  2010cited by this paper
• Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

  2010cited by this paper
• Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.

  2010cited by this paper
• Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA

  2010cited by this paper
• Factors Affecting Template Usage in the Development of K65R Resistance in Subtype C Variants of HIV Type-1

  2010cited by this paper
• Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men

  2010cited by this paper
• Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance

  2010cited by this paper
• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  2010cited by this paper
• Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

  2010cited by this paper
• Tenofovir Disoproxil Fumarate and Bone Mineral Density: A 60-Month Longitudinal Study in a Cohort of H V -Infected Youths

  2010cited by this paper
• Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance

  2009cited by this paper
• Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicity

  2009cited by this paper
• Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

  2009cited by this paper
• Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial

  2009cited by this paper
• Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

  2009cited by this paper
• A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

  2009cited by this paper
• The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

  2009cited by this paper
• Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

  2009cited by this paper
• Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first‐line boosted highly active antiretroviral therapy based on protease inhibitors: meta‐regression analysis of 12 clinical trials in 5168 patients

  2009cited by this paper
• Population Pharmacokinetics of Tenofovir in HIV‐1‐Infected Pregnant Women and Their Neonates (ANRS 12109)

  2009cited by this paper
• Renal function with use of a tenofovir-containing initial antiretroviral regimen

  2009cited by this paper
• Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

  2009cited by this paper
• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• Cost and Cost-Effectiveness of Switching From Stavudine to Tenofovir in First-Line Antiretroviral Regimens in South Africa

  2008cited by this paper
• Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis

  2008cited by this paper
• Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.

  2008cited by this paper
• Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients The SMART/INSIGHT and the D:A:D Study Groups M

  2008cited by this paper
• Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

  2008cited by this paper
• Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

  2008cited by this paper
• Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine in Semen and Plasma of HIV-1-Infected Men

  2008cited by this paper
• Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates

  2008cited by this paper
• Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

  2007cited by this paper
• Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1

  2007cited by this paper
• Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women.

  2007cited by this paper
• Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

  2007cited by this paper
• Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

  2006cited by this paper
• Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision.

  2006cited by this paper
• Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children

  2006cited by this paper
• The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations

  2006cited by this paper
• Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine

  2006cited by this paper
• Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

  2005cited by this paper
• A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children

  2005cited by this paper
• Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

  2005cited by this paper
• British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

  2005cited by this paper
• In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

  2005cited by this paper
• Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.

  2005cited by this paper
• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

  2004cited by this paper
• Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to reduce Perinatal HIV-1Transmission in the United States

  2003cited by this paper
• Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.

  2003cited by this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 1091–1098 (2001) METABOLISM OF GS-7340, A NOVEL PHENYL MONOPHOSPHORAMIDATE INTRACELLULAR PRODRUG OF PMPA, IN BLOOD

  2003cited by this paper
• Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors.

  2002cited by this paper
• PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV‐1 infection

  2002cited by this paper
• Differential Effects of Nucleoside Analogs on Oxidative Phosphorylation in Human Pancreatic Cells

  2001cited by this paper
• Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.

  2000cited by this paper
• Mitochondrial myopathy caused by long-term zidovudine therapy.

  1990cited by this paper

• Machine learning aided multiscale modelling of the HIV-1 infection in the presence of NRTI therapy

  2023cites this paper
• Phomoarcherin B as a novel HIV-1 reverse transcriptase RNase H activity inhibitor: conclusions from comprehensive computational analysis

  2021cites this paper
• Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19

  2021cites this paper
• Raman-based metabonomics unravels metabolic changes related to a first-line tenofovir-based treatment in a small cohort of South African HIV-infected patients.

  2020cites this paper
• Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

  2020cites this paper
• “It made me more confident that I have it under control”: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain

  2020cites this paper
• Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies

  2019cites this paper
• Accelerated aging in perinatally HIV-infected children: clinical manifestations and pathogenetic mechanisms

  2018cites this paper
• Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine).

  2018cites this paper
• Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued

  2017cites this paper
• Mutations of mtDNA polymerase-γ and hyperlactataemia in the HIV-infected Zulu population of South Africa.

  2016cites this paper
• Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus

  2015cites this paper
• [Incidence of cancer in Chilean HIV-infected children].

  2015cites this paper
• Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells

  2015cites this paper
• Efficacy of antiviral chemotherapy for retrovirus-infected cats

  2015cites this paper
• Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells.

  2014influential citation
• Pediatric human immunodeficiency virus infection and cancer in the highly active antiretroviral treatment (HAART) era.

  2014cites this paper
• Protéine kinase GCN2 et phosphorylation de l’intégrase du VIH-1

  2014cites this paper
• Nucleoside-Sparing Antiretroviral Regimens

  2014cites this paper
• Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

  2013cites this paper
• Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial

  2013cites this paper
• Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

  2010cites this paper